Novo Nordisk’s Legal and Commercial Offensive Faces a Generics Countdown

As weight loss drug battle heats up, Novo sues Lilly claiming misleading ads

Novo Nordisk sued rival Eli Lilly in a U.S. federal court on July 21, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.

Jim Cramer Urges Novo Nordisk (NYSE: NVO) To Beat Eli Lilly (NYSE: LLY) In The Market Rather Than The Courtroom

Novo Nordisk A/S (NYSE: NVO) has filed a lawsuit against rival weight loss drug maker Eli Lilly and Company (NYSE: LLY), alleging the company ran misleading advertisements about its products. Novo Nordisk claims Lilly relied on outdated clinical trials and misleading dosage information to inflate the efficacy claims of its weight loss drugs compared to Novo Nordisk’s own offerings. Lilly pushed back firmly, stating that its trials were conducted…

Novo Nordisk’s Legal and Commercial Offensive Faces a Generics Countdown

Novo Nordisk is waging a multi-front campaign to defend its GLP-1 empire, but the clock is ticking louder than any courtroom gavel. The Danish drugmaker has filed two separate lawsuits — one against Eli Lilly and another against Hims & Hers — while simultaneously rolling out a direct-to-consumer subscription model for Wegovy, all as the […] The post Novo Nordisk’s Legal and Commercial Offensive Faces a Generics Countdown appeared first on NewsCa…